DeWoskin will oversee NeuraLight’s commercial strategies and policies as the platform continues to digitize neurology
NeuraLight appointed Vivian DeWoskin as Chief Commercial Officer. The company if focused on digitizing neurological evaluation and care for Parkinson’s, Alzheimer’s, ALS, and Multiple Sclerosis. Most recently, DeWoskin served as VP, Head of Strategy at Komodo Health, a software company building solutions for the life sciences on a foundation of longitudinal patient data and insights.
In her role at NeuraLight, DeWoskin will oversee the implementation of new commercialization strategies as NeuraLight begins its next phase of growth and expands its strategic partnerships with pharma and biotech companies.
“I was drawn to the NeuraLight team by their dedication to improving the lives of patients with neurodegenerative conditions through innovative and accessible technology solutions,” DeWoskin said. “What NeuraLight has developed has enormous potential for changing the diagnostic and treatment landscape, and I am thrilled for the opportunity to be a part of bringing it to patients and providers.”
While at Komodo Health, DeWoskin contributed to the development and commercialization of multiple products for life sciences companies, patient advocacy organizations, and other customer types across the healthcare ecosystem. She played a significant role in the creation of the company’s proprietary COVID-19 patient dataset, and helped lead Komodo’s efforts to address health equity and race-based disparities in care through commercial partnerships with biopharma. She also led teams responsible for market strategy and innovation across all customer segments as the company received $220M in its Series E funding round.
Throughout her career, DeWoskin has served as a trusted advisor to numerous pharma and biotech companies, leveraging her expertise to drive growth and launch new products successfully.
Before Komodo Health, DeWoskin spent eight years at Trinity Life Sciences, an advisory company that provides insights & analytics to pharma and emerging biotech companies. During her time there, DeWoskin specialized in helping clients bring novel therapies to market, particularly in the areas of oncology, neurology, and rare disease. She held various consulting roles at the company before leaving as the Director of Commercial and Business Development. Vivian holds an MBA from Berkeley-Haas, and a degree in Cognitive & Computational Neuroscience from Princeton University.
At NeuraLight, DeWoskin will closely work with CEO, Micha Breakstone, as she spearheads the creation of new partnerships with pharma and biotech companies to help bring digital biomarkers to market via NeuraLight’s artificial intelligence and machine learning platform.
“Vivian’s passion for healthcare and technology will be a major asset to our team as we expand our partnerships,” said NeuraLight CEO Micha Breakstone. “Her track record of success across Commercial Strategy and Partnerships, coupled with her devotion to helping others, make her a natural fit for the team, and I’m excited to work with her and learn from her as we take NeuraLight to the next stage.”
DeWoskin’s addition comes on the heels of a momentous year for NeuraLight. In March 2023, the company won the SXSW Innovation Award for Health and MedTech. Previously, NeuraLight raised a $25 million series A in May 2022 to support its goals of providing drug developers with a platform to more effectively measure therapeutic effect, help support an increase in the probability of success for novel neurological therapeutics, and usher in a new era of precision medicine for neurology.